Skip to main content

Table 1 Patient group characteristics

From: A cohort study evaluating the association between concurrent mental disorders, mortality, morbidity, and continuous treatment retention for patients in opioid agonist treatment (OAT) across Ontario, Canada, using administrative health data

Variable Concurrent mental and opioid use disorder Opioid use disorder only Standardized differences (sd)
  N = 48,679 (87.0) 7245 (13.0)  
Age    0.3
 15 to 24 8.727 (17.9) 1514 (20.9)  
 25 to 34 16,148 (33.2) 2859 (39.5)  
 35 to 44 10,712 (22.0) 1383 (19.1)  
 45 to 54 8812 (18.1) 989 (13.7)  
 55 to 64 3348 (6.9) 338 (4.7)  
 +65+ 932 (1.9) 162 (2.2)  
Sex    0.2
 +Male 30,654 (63.0) 5575 (77.0)  
 Female 18,025 (37.0) 1670 (23.1)  
Geography    0.2
 +Southern urban 37,887 (77.8) 5209 (71.9)  
 Northern rural 2240 (4.6) 593 (21.0)  
 Northern urban 4533 (9.3) 761 (10.5)  
 Southern rural 4016 (8.2) 682 (9.4)  
Income    0.0
 +5 5532 (11.5) 734 (10.4)  
 4 7014 (14.6) 1078 (15.2)  
 3 8690 (18.1) 1282 (18.1)  
 2 10,886 (22.6) 1613 (22.7)  
 1 (lowest) 16,020 (33.3) 2388 (33.7)  
HIV positive 390 (0.8) 21 (0.3) 0.1
Deep-tissue infection 1584 (3.3) 92 (1.3) 0.1
All-cause mortality 2485 (5.1) 227 (3.1) 0.1
*One year continuous OAT 8757 (37.6) 903 (35.7) 0.2
*Mean days buprenorphine (SD) 55.0 (167.8) 34.8 (121.8) < .0001
*Mean days methadone (SD) 356.8 (441.0) 344.6 (409.8) < .0.042
  1. sd standardized difference, SD standard deviation
  2. +Reference group
  3. *Ontario Drug Benefit plan subgroup analysis (n = 28,500)